BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 21349590)

  • 21. [Mutations in the US2 and glycoprotein B genes of the equine herpesvirus 1 vaccine strain RacH have no effects on its attenuation].
    Neubauer A; Meindl A; Osterrieder N
    Berl Munch Tierarztl Wochenschr; 1999 Sep; 112(9):351-4. PubMed ID: 10507185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro cytotoxicity of serum and peripheral blood leukocytes for equine herpesvirus type 1-infected target cells.
    Wilks CR
    Am J Vet Res; 1977 Jan; 38(1):117-21. PubMed ID: 189645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C-C motif chemokine ligand (CCL) production in equine peripheral blood mononuclear cells identified by newly generated monoclonal antibodies.
    Schnabel CL; Wemette M; Babasyan S; Freer H; Baldwin C; Wagner B
    Vet Immunol Immunopathol; 2018 Oct; 204():28-39. PubMed ID: 30596378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Equine interferon gamma synthesis in lymphocytes after in vivo infection and in vitro stimulation with EHV-1.
    Paillot R; Daly JM; Juillard V; Minke JM; Hannant D; Kydd JH
    Vaccine; 2005 Aug; 23(36):4541-51. PubMed ID: 15913852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Equine herpesvirus 1 mutants devoid of glycoprotein B or M are apathogenic for mice but induce protection against challenge infection.
    Neubauer A; Beer M; Brandmüller C; Kaaden OR; Osterrieder N
    Virology; 1997 Dec; 239(1):36-45. PubMed ID: 9426444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of equine herpesvirus-specific effector and memory cytotoxic immunity in the equine upper respiratory tract.
    Breathnach CC; Yeargan MR; Timoney JF; Allen GP
    Vet Immunol Immunopathol; 2006 May; 111(1-2):117-25. PubMed ID: 16472871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination.
    Minke JM; Fischer L; Baudu P; Guigal PM; Sindle T; Mumford JA; Audonnet JC
    Vet Immunol Immunopathol; 2006 May; 111(1-2):47-57. PubMed ID: 16580075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Equine herpesvirus-1 suppresses type-I interferon induction in equine endothelial cells.
    Sarkar S; Balasuriya UB; Horohov DW; Chambers TM
    Vet Immunol Immunopathol; 2015 Oct; 167(3-4):122-9. PubMed ID: 26275803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunologic relationships between equine herpesvirus type 1 (equine abortion virus) and type 4 (equine rhinopneumonitis virus).
    Fitzpatrick DR; Studdert MJ
    Am J Vet Res; 1984 Oct; 45(10):1947-52. PubMed ID: 6208822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum antibody responses to equine herpesvirus 1 glycoprotein D in horses, pregnant mares and young foals.
    Foote CE; Love DN; Gilkerson JR; Rota J; Trevor-Jones P; Ruitenberg KM; Wellington JE; Whalley JM
    Vet Immunol Immunopathol; 2005 May; 105(1-2):47-57. PubMed ID: 15797474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Innate immunity during Equid herpesvirus 1 (EHV-1) infection.
    Bridges CG; Edington N
    Clin Exp Immunol; 1986 Jul; 65(1):172-81. PubMed ID: 2431815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune escape of equine herpesvirus 1 and other herpesviruses of veterinary importance.
    van der Meulen KM; Favoreel HW; Pensaert MB; Nauwynck HJ
    Vet Immunol Immunopathol; 2006 May; 111(1-2):31-40. PubMed ID: 16472872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the host immune response on the development of equine herpesvirus myeloencephalopathy in horses.
    Giessler KS; Goehring LS; Jacob SI; Davis A; Esser MM; Lee Y; Zarski LM; Weber PSD; Hussey GS
    J Gen Virol; 2024 May; 105(5):. PubMed ID: 38767608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody and cellular immune responses following DNA vaccination and EHV-1 infection of ponies.
    Soboll G; Hussey SB; Whalley JM; Allen GP; Koen MT; Santucci N; Fraser DG; Macklin MD; Swain WF; Lunn DP
    Vet Immunol Immunopathol; 2006 May; 111(1-2):81-95. PubMed ID: 16549215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Equine rhinopneumonitis virus (herpesvirus type 1): attenuation in stable monkey cell line.
    Purdy CW; Ford SJ; Grant WF
    Am J Vet Res; 1977 Aug; 38(8):1211-5. PubMed ID: 199093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predominant interferon-γ-mediated expression of CXCL9, CXCL10, and CCL5 proteins in the brain during chronic infection with Toxoplasma gondii in BALB/c mice resistant to development of toxoplasmic encephalitis.
    Wen X; Kudo T; Payne L; Wang X; Rodgers L; Suzuki Y
    J Interferon Cytokine Res; 2010 Sep; 30(9):653-60. PubMed ID: 20626297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of latent, neuropathogenic equine herpesvirus-1 in the Thoroughbred broodmare population of central Kentucky.
    Allen GP; Bolin DC; Bryant U; Carter CN; Giles RC; Harrison LR; Hong CB; Jackson CB; Poonacha K; Wharton R; Williams NM
    Equine Vet J; 2008 Mar; 40(2):105-10. PubMed ID: 18089469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intranasal IgG4/7 antibody responses protect horses against equid herpesvirus-1 (EHV-1) infection including nasal virus shedding and cell-associated viremia.
    Perkins G; Babasyan S; Stout AE; Freer H; Rollins A; Wimer CL; Wagner B
    Virology; 2019 May; 531():219-232. PubMed ID: 30928700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Equine herpesvirus type 1 pUL56 modulates innate responses of airway epithelial cells.
    Soboll Hussey G; Ashton LV; Quintana AM; Van de Walle GR; Osterrieder N; Lunn DP
    Virology; 2014 Sep; 464-465():76-86. PubMed ID: 25046270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Equine herpesvirus type 1 infection induces procoagulant activity in equine monocytes.
    Yeo WM; Osterrieder N; Stokol T
    Vet Res; 2013 Mar; 44(1):16. PubMed ID: 23497076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.